Mankind Pharma Approves FY26 Financial Results, Plans ₹500 Crore Investment in Subsidiary
Mankind Pharma Limited, a leading player in the pharmaceutical sector, announced the approval of its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board meeting also saw approval for a strategic additional investment of up to ₹500 crores in its wholly owned subsidiary, Mankind Medicare Private Limited.In significant governance and financial updates, the company approved the realignment of security cover for its Non-Convertible Debentures (NCDs) following the redemption of an NCD tranche of ₹1,250 Crores on April 16, 2026. The board confirmed that the existing security cover will be replaced with tangible and intangible assets.
Financial Highlights and Reporting
The company presented its audited consolidated financial results for the period ending March 31, 2026. The consolidated revenue from operations for the year ended March 31, 2026, was ₹14,636.43 crore, compared to ₹12,744.23 crore for the previous year.The total consolidated assets stood at ₹28,079.53 crore as of March 31, 2026, compared to ₹27,759.53 crore in the previous year. The total equity and liabilities stood at ₹16,561.05 crore on the same date.
Key financial data points for the company, including metrics and asset/liability statements, are presented below:
Consolidated Financial Metrics (in ₹ Crores)
| Metric | Quarter ended 31.03.2026 | Quarter ended 31.12.2025 | Quarter ended 31.03.2025 | Year ended 31.03.2026 | Year ended 31.03.2025 |
|---|---|---|---|---|---|
| Total Income | 3,557.22 | 3,639.95 | 3,330.70 | 14,636.43 | 12,744.23 |
| Total Expenses | 2,877.88 | 3,027.57 | 2,817.59 | 12,185.69 | 10,240.14 |
| Profit for the period/year | 559.42 | 413.88 | (4.34) | 1,938.10 | 4,53.20 |
| Total comprehensive Income | 588.36 | 419.83 | 410.73 | 1,995.14 | 2,002.83 |
Consolidated Assets and Liabilities as at March 31 (₹ Crores)
| Category | As at 31.03.2026 (Audited) | As at 31.03.2025 (Audited) |
|---|---|---|
| Total Non-current assets | 21,125.33 | 20,771.26 |
| Total Current assets | 6,954.20 | 6,988.27 |
| Total assets | 28,079.53 | 27,759.53 |
| Total Equity | 16,561.05 | 14,568.18 |
| Total Non-current liabilities | 29,945.01 | 7,527.79 |
| Total Current liabilities | 6,518.48 | 13,191.35 |
| Total liabilities | 13,191.35 | 11,176.63 |
| Total equity and liabilities | 28,079.53 | 27,759.53 |
Key Corporate and Operational Decisions
During the board meeting held on May 19, 2026, the company made several key operational and governance decisions:- New Investment: The board approved an additional investment of up to ₹500 crores in Mankind Medicare Private Limited, a wholly owned subsidiary, which funds will be utilized for capacity expansion and setting up a plant. This investment is expected to maintain Medicare's status as a wholly-owned subsidiary.
- Leadership Changes: The board took note of the resignation of Mr. Pramod Gokhale, Global Chief Information Officer. His resignation is effective from the close of business hours on May 31, 2026.
- Director Re-appointment: Mr. Satish Kumar Sharma was re-appointed as Whole-Time Director for another five-year term, effective from September 23, 2026.
- Auditor Appointment: M/s. M. K. Kulshrestha & Associates, Cost Accountants, were re-appointed as the Cost Auditors for the financial year 2026-27.
- Cost Management: To strengthen the company’s cash position for future business expansion, the Executive Chairman, Vice Chairman & Managing Director, and Chief Executive Officer & Whole Time Director collectively decided not to draw their commission for the financial year 2025-26.
Statutory Updates and Security Cover
The board also confirmed approvals related to debt and compliance:- NCD Security Cover: The company approved the realignment of the security cover for existing Non-Convertible Debentures (NCDs) bearing ISIN Nos. INE634S07025 and INE634S07033. This realignment follows the redemption of NCDs totaling ₹1,250 Crores on April 16, 2026, and the existing security cover will be replaced with tangible and intangible assets.
- Director Tenure: Mr. Satish Kumar Sharma's term as Whole-Time Director is set to expire, requiring approval by the members at the ensuing 35th Annual General Meeting (AGM).
The company has maintained a strong focus on compliance and governance, ensuring continuous regulatory adherence concerning its listed instruments.
MANKIND Stock Price Movement
On Tuesday, Mankind Pharma Limited shares slipped by 1.03% to settle at ₹2492.6. The stock saw 574,210 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: